Bank of America has increased its price target for Guardant Health (GH, Financial) to $60, up from the previous target of $56, while maintaining a Buy rating on the company's stock. The adjustment comes despite a generally pessimistic outlook for the Life Sciences and Diagnostic Tools sector as well as Contract Research Organizations.
Investors are cautious as these industries face multiple policy shifts initiated during the Trump Administration. Key challenges include reductions in the National Institutes of Health budget and the impact of global tariffs. Additionally, broader economic uncertainties, particularly those related to China, add to the complexities impacting these sectors. Nevertheless, Guardant Health seems positioned to weather these headwinds according to Bank of America's revised analysis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 21 analysts, the average target price for Guardant Health Inc (GH, Financial) is $55.29 with a high estimate of $65.00 and a low estimate of $20.00. The average target implies an upside of 22.44% from the current price of $45.16. More detailed estimate data can be found on the Guardant Health Inc (GH) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, Guardant Health Inc's (GH, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Guardant Health Inc (GH, Financial) in one year is $47.05, suggesting a upside of 4.2% from the current price of $45.155. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Guardant Health Inc (GH) Summary page.
